U.S., Europe, and Asia Pacific Molecular Diagnostics Market, by Product Type (Reagents and Kits & Instruments), by Technology (PCR-based (Liquid Biopsy Testing, Tissue Testing) and NGS-based (Liquid Biopsy Testing, Tissue Testing)), by Application, (Genet

U.S., Europe, and Asia Pacific Molecular Diagnostics Market, by Product Type (Reagents and Kits & Instruments), by Technology (PCR-based (Liquid Biopsy Testing, Tissue Testing) and NGS-based (Liquid Biopsy Testing, Tissue Testing)), by Application, (Genetic Testing, Oncology, Microbiology, STDs, Blood Screening, Virology, Tissue Typing, Prenatal Diagnosis, Others), by End Users, (Hospitals, Clinics, and Ambulatory Surgery Centers), and by Region (U.S., Europe, and Asia Pacific) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

For detecting the disturbance between specific sequences in DNA or RNA, molecular diagnostics tests are used, which may be associated with disease. The other factors which lead to various diseases are disturbance between single nucleotide polymorphism, rearrangements, insertions, and others. Infectious diseases, virology, oncology and STDs are the diseases that are diagnosed by utilizing molecular diagnostic test.
Molecular diagnostics has the capacity of detecting specific disease which access in supplying accurate medicine to patients. On research and development of precision medicine various government economies are focused on diagnostic tests, which is estimated to drive the growth of the U.S., Europe, and Asia Pacific molecular diagnostics market over the forecast period.
The U.S., Europe, and Asia Pacific molecular diagnostics market is estimated to be valued at US$ 7,147 Mn in 2021 and is expected to witness a robust CAGR of 10.7% during the forecast period (2021-2028).
Market Dynamics
Increasing applications of biomarkers, new product launches by market players with increasing government initiatives, increasing demand for molecular diagnostic tests, and increasing adoption of inorganic growth strategies such as mergers, acquisitions, partnerships, and collaborations by key players operating in the market are the major factors that are expected to drive growth of the U.S., Europe, and Asia Pacific molecular diagnostics market.
The growth of molecular diagnostics market is expected to increase the research and development for identification of biomarkers which leads to new molecular diagnostic tests development. For instance, in February 2018, authorization to Banyan Biomarkers, Inc., a biotech company, was given by the U.S. FDA (Food and Drug Administration) for traumatic brain injury, for first diagnostic blood test.
Key features of the study:
This report provides in-depth analysis of the U.S., Europe, and Asia Pacific molecular diagnostics market provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the U.S., Europe, and Asia Pacific molecular diagnostics market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Abbott Laboratories, Hologic, Inc., Grifols, S.A., Qiagen N.V., F.Hoffmann-La Roche Ltd., Siemens Healthineers, Becton, Dickinson and Company, Beckmann Coulter, Inc., Bio-Rad Laboratories, and Thermo Fisher Scientific Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The U.S., Europe, and Asia Pacific molecular diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S., Europe, and Asia Pacific molecular diagnostics market
Detailed Segmentation:
U.S., Europe, and Asia Pacific Molecular Diagnostics Market, by Product Type:
Reagents
Kits & Instruments
U.S., Europe, and Asia Pacific Molecular Diagnostics Market, by Technology:
PCR-based
Liquid Biopsy Testing
Tissue Testing
NGS-based
Liquid Biopsy Testing
Tissue Testing
U.S., Europe, and Asia Pacific Molecular Diagnostics Market, by Application:
Genetic Testing
Oncology
Microbiology
STDs
Blood Screening
Virology
Tissue Typing
Prenatal Diagnosis
Others
U.S., Europe, and Asia Pacific Molecular Diagnostics Market, by End Users:
Hospitals
Clinics
Ambulatory Surgery Centers
U.S., Europe, and Asia Pacific Molecular Diagnostics Market, by Country:
U.S.
Europe
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Company Profiles
Abbott Laboratories*
Company highlights
Product Portfolio
Key Highlights
Financial performance
Strategies
Hologic, Inc.
Grifols, S.A.
Qiagen N.V.
F.Hoffmann-La Roche Ltd.
Siemens Healthineers,
Becton, Dickinson and Company,
Beckmann Coulter, Inc.
Bio-Rad Laboratories
Thermo Fisher Scientific Inc.
“*” marked represents similar segmentation in other categories in the respective section.